Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephanie Lheureux

Showing results (91-100 of 134) with videos related to

Pageof 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2023
Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical CancerKathy Han, Jinfeng Zou, Zhen Zhao, et al.
Nature Communications|March 16, 2023
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinomaAinhoa Madariaga, Swati Garg, Nairi Tchrakian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous CarcinomaJoyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
BMC Cancer|March 19, 2025
Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)Daniel Marbach, Jurriaan Brouer-Visser, Laura Brennan, et al.
Genome Medicine|November 2, 2018
Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivorsS Y Cindy Yang, Stephanie Lheureux, Katherine Karakasis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2020
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition ProgressionStephanie Lheureux, Ana Oaknin, Swati Garg, et al.
Journal of Oncology Practice|September 25, 2019
Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic CancerYeh Chen Lee, Nazlin Jivraj, Lisa Wang, et al.
Journal of the National Cancer Institute|May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Electronic malignant bowel obstruction symptom monitoring smartphone application for patients with gynecologic cancersAinhoa Madariaga, Nazlin Jivraj, Pamela Soberanis Pina, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 31, 2024
Electronic malignant bowel obstruction symptom monitoring smartphone application for patients with gynecologic cancersAinhoa Madariaga, Nazlin Jivraj, Pamela Soberanis Pina, et al.
Pageof 14

Showing results (91-100 of 134) with videos related to

Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2023
Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical CancerKathy Han, Jinfeng Zou, Zhen Zhao, et al.
Nature Communications|March 16, 2023
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinomaAinhoa Madariaga, Swati Garg, Nairi Tchrakian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous CarcinomaJoyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
BMC Cancer|March 19, 2025
Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)Daniel Marbach, Jurriaan Brouer-Visser, Laura Brennan, et al.
Genome Medicine|November 2, 2018
Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivorsS Y Cindy Yang, Stephanie Lheureux, Katherine Karakasis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2020
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition ProgressionStephanie Lheureux, Ana Oaknin, Swati Garg, et al.
Journal of Oncology Practice|September 25, 2019
Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic CancerYeh Chen Lee, Nazlin Jivraj, Lisa Wang, et al.
Journal of the National Cancer Institute|May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Electronic malignant bowel obstruction symptom monitoring smartphone application for patients with gynecologic cancersAinhoa Madariaga, Nazlin Jivraj, Pamela Soberanis Pina, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 31, 2024
Electronic malignant bowel obstruction symptom monitoring smartphone application for patients with gynecologic cancersAinhoa Madariaga, Nazlin Jivraj, Pamela Soberanis Pina, et al.
Pageof 14